» Articles » PMID: 12588987

Beta-catenin Binds to the Activation Function 2 Region of the Androgen Receptor and Modulates the Effects of the N-terminal Domain and TIF2 on Ligand-dependent Transcription

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2003 Feb 18
PMID 12588987
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Beta-catenin is a multifunctional molecule that is activated by signaling through WNT receptors. beta-Catenin can also enhance the transcriptional activity of some steroid hormone receptors such as the androgen receptor and retinoic acid receptor alpha. Androgens can affect nuclear translocation of beta-catenin and influence its subcellular distribution. Using mammalian two-hybrid binding assays, analysis of reporter gene transcription, and coimmunoprecipitation, we now show that beta-catenin binds to the androgen receptor ligand-binding domain (LBD) and modulates the transcriptional effects of TIF2 and the androgen receptor N-terminal domain (NTD). In functional assays, beta-catenin bound to androgen receptor only in the presence of ligand agonists, not antagonists. Beta-catenin binding to the androgen receptor LBD was independent of and cooperative with the androgen receptor NTD and the p160 coactivator TIF2, both of which bind to the activation function 2 (AF-2) region of the androgen receptor. Different mutations of androgen receptor helix 3 amino acids disrupted binding of androgen receptor NTD and beta-catenin. beta-Catenin, androgen receptor NTD, and TIF2 binding to the androgen receptor LBD were affected similarly by a subset of helix 12 mutations, but disruption of two sites on helix 12 affected only binding of beta-catenin and not of TIF2 or the androgen receptor NTD. Mutational disruption of each of five LXXLL peptide motifs in the beta-catenin armadillo repeats did not disrupt either binding to androgen receptor or transcriptional coactivation. ICAT, an inhibitor of T-cell factor 4 (TCF-4), and E-cadherin binding to beta-catenin also blocked binding of the androgen receptor LBD. We also demonstrated cross talk between the WNT and androgen receptor signaling pathways because excess androgen receptor could interfere with WNT signaling and excess TCF-4 inhibited the interaction of beta-catenin and androgen receptor. Taken together, the data show that beta-catenin can bind to the androgen receptor LBD and modulate the effects of the androgen receptor NTD and TIF2 on transcription.

Citing Articles

Modulation of the canonical Wnt activity by androgen signaling in prostate epithelial basal stem cells.

Horton C, Liu Y, Wang J, Green J, Tsyporin J, Chen B Stem Cell Reports. 2023; 18(6):1355-1370.

PMID: 37172587 PMC: 10277819. DOI: 10.1016/j.stemcr.2023.04.003.


Unravelling the Role of Kinases That Underpin Androgen Signalling in Prostate Cancer.

Miller K, Asim M Cells. 2022; 11(6).

PMID: 35326402 PMC: 8946764. DOI: 10.3390/cells11060952.


Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer.

Patel M, Pennel K, Quinn J, Hood H, Chang D, Biankin A Br J Cancer. 2022; 126(12):1704-1714.

PMID: 35173303 PMC: 9174220. DOI: 10.1038/s41416-022-01729-2.


Endocrine Disruptors and Prostate Cancer.

Corti M, Lorenzetti S, Ubaldi A, Zilli R, Marcoccia D Int J Mol Sci. 2022; 23(3).

PMID: 35163140 PMC: 8835300. DOI: 10.3390/ijms23031216.


Androgen Receptor-Mediated Nuclear Transport of NRDP1 in Prostate Cancer Cells Is Associated with Worse Patient Outcomes.

Steele T, Sam A, Evans S, Browning E, Krig S, Macias K Cancers (Basel). 2021; 13(17).

PMID: 34503235 PMC: 8430998. DOI: 10.3390/cancers13174425.


References
1.
Quigley C, De Bellis A, Marschke K, El-Awady M, Wilson E, French F . Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev. 1995; 16(3):271-321. DOI: 10.1210/edrv-16-3-271. View

2.
Adachi M, Takayanagi R, Tomura A, Imasaki K, Kato S, Goto K . Androgen-insensitivity syndrome as a possible coactivator disease. N Engl J Med. 2000; 343(12):856-62. DOI: 10.1056/NEJM200009213431205. View

3.
Langley E, Zhou Z, Wilson E . Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem. 1995; 270(50):29983-90. DOI: 10.1074/jbc.270.50.29983. View

4.
McInerney E, Rose D, FLYNN S, Westin S, Mullen T, Krones A . Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev. 1998; 12(21):3357-68. PMC: 317227. DOI: 10.1101/gad.12.21.3357. View

5.
Simental J, Sar M, Lane M, French F, Wilson E . Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem. 1991; 266(1):510-8. View